Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
UNSPSC Code:
12352202
EC Number:
232-718-7
NACRES:
NA.32
Form:
lyophilized powder
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
product line
BioReagent
form
lyophilized powder
potency
erythroagglutination activity (Does not agglutinate a 2% suspension of human erythrocytes at 250 μg lectin/ml.), ≤1.0 μg per mL leucoagglutination activity, ≤5 μg per mL mitogenic activity (Bromdeoxyuridine incorporation in human peripheral blood mononuclear cells)
technique(s)
cell culture | mammalian: suitable
impurities
salt, free
solubility
DPBS: 5 mg/mL, slightly hazy, colorless
suitability
leucocyte agglutination activity tested
storage temp.
2-8°C
General description
Lectins are carbohydrate-binding proteins, which contains four subunits with a molecular weight of 125 kDa. Leucoagglutinin PHA-L is a plant lectin, which is transported by the neurons in the central nervous system.
Application
Lectin from Phaseolus vulgaris (red kidney bean) has been used:
- it has been used as a positive control to treat cells
- to stimulate cell culture for the analysis of lymphocyte proliferation
- to stimulate T cells
Biochem/physiol Actions
Lectin agglutinates cells and precipitates polysaccharides and glycoproteins. It is associated with toxic allergens and hemagglutinins. Lectin exhibits anti-cancer, anti-human immunodeficiency virus (anti-HIV) and anti-microbial infection properties. Lectin inhibits mucosal atrophy, lowers type 2 diabetes and obesity, enhances nutrient absorption and regulates drug targeting.
La PHA consta de dos especies moleculares, la eritroaglutinina (PHA-E), que tiene poca actividad mitógena y elevada actividad de eritroaglutinina, y la leoucoaglutinina (PHA-L), que tiene elevada actividad mitógena y leoucoaglutinante, pero muy baja actividad eritroaglutininante
La PHA-E no es específica de grupo sanguíneo, pero la aglutinación puede ser inhibida por ciertos oligosacáridos. La PHA-P es la forma proteica de la PHA antes de la separación y la purificación de la eritroaglutinina y la leoucoaglutinina. La PHA-M es la forma mucoproteínica. Los conjugados se preparan a partir de las correspondientes lectinas purificadas.
La PHA-E no es específica de grupo sanguíneo, pero la aglutinación puede ser inhibida por ciertos oligosacáridos. La PHA-P es la forma proteica de la PHA antes de la separación y la purificación de la eritroaglutinina y la leoucoaglutinina. La PHA-M es la forma mucoproteínica. Los conjugados se preparan a partir de las correspondientes lectinas purificadas.
Analysis Note
Agglutination activity is expressed in μg/ml and is determined from serial dilutions of a 1 mg/ml solution. This activity is the lowest concentration to agglutinate a suspension of either human erythrocytes (2% in phosphate buffered saline, pH 6.8) or human leukocytes (107 per mL in saline) after 1 hr incubation at 25 °C.
Still not finding the right product?
Explore all of our products under Lectina de Phaseolus vulgaris (frijol rojo)
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Contenido relacionado
Instructions
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak, et al.
Annals of the Rheumatic Diseases (2021)
Patricia Kaaijk et al.
Scientific reports, 11(1), 13664-13664 (2021-07-03)
Mumps is nowadays re-emerging despite vaccination. The contribution of T cell immunity to protection against mumps has not been clearly defined. Previously, we described a set of 41 peptides that were eluted from human leukocyte antigen (HLA) class I molecules
Haifeng Huang et al.
Acta pharmaceutica Sinica. B, 10(7), 1321-1330 (2020-09-03)
JS001 (toripalimab) is a humanized IgG monoclonal antibody which strongly inhibits programmed cell death protein 1 (PD1). In this study, we used a different iodine isotype (nat/124/125I) to label JS001 probes to target the human PD1 (hPD1) antigen. In vitro